Ulcerative Colitis Clinical Trial
Official title:
Feasibility and Acceptability of an Inflammatory Bowel Disease Self-management Website and Home Faecal Calprotectin Monitoring After Treatment De-escalation
6 month exploratory feasibility study to assess if a combination of MyMedicalRecord supported self-management website and a home faecal calprotectin smartphone testing kit is a feasible and acceptable means for patients to monitor for signs of relapse after treatment de-escalation.
IBD can be challenging to manage as disease flares are often unpredictable and rarely
coincide with scheduled outpatient appointments. Websites are a novel way of assisting
patients to take more control over monitoring and managing symptoms and have been shown to
improve outcomes in some chronic diseases. The My Medical Record (MyMR) webiste was developed
to help patients learn about IBD, access test results, monitor symptoms, and manage their
medications, with email support from the IBD team.
The use of home faecal calprotectin monitoring will also be explored. This marker of IBD
activity is normally performed in hospital laboratories and becomes elevated before the onset
of clinical symptoms of an IBD flare. New technologies enable patients to perform the test at
home with the aid of a smartphone application.
A 6 month exploratory feasibility study will be conducted to assess if a combination of MyMR
and a home faecal testing kit is a feasible and acceptable means for patients to monitor
their illness. Their use will be targeted to patients who have recently stopped (or reduced)
a treatment for IBD, as up to 50% of these patients may have a disease flare within a year.
Interventions
- Clinic appointments Study participants will not be required to attend any routine
outpatient follow up appointments for the 6 month study period, after which they will be
reviewed by a member of the IBD team.
- Questionnaires and interviews Partcipants will receive questionnaires and a sample will
also undergo interviews to explore their views regarding the website and stool test.
- Website
Participants will be encouraged to use all functions of the website at least monthly:
1. Secure email messaging service
2. IBD educational material
3. Stool, nutritional and flare journals
4. Blood and test results
5. Faecal calprotectin monitoring - monthly testing (or sooner if symptoms of a flare-up)
using QuantonCal home faecal calprotectin smartphone application. Participants will test
and monitor their FC levels monthly. The results will be overseen by the IBD team who
will make contact within a week in the event of abnormal results if the participant has
not already done so.
- Blood tests All participants will have a routine blood test at 0 and 6 months.
Those taking azathioprine, mercaptopurine and methotrexate should continue regular
blood monitoring (minimum of 3 monthly FBC, U&E, LFT and CRP) as usual practice.
Participants will be provided with blood test results and explanations of their
significance via MyMR. The results will be overseen by the IBD team who will make
contact within a week in the event of abnormal results if the patient has not
already done so.
- Safety Patients can contact the IBD team the email messaging service at any time
for advice and support.
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05702879 -
Combined Microbiota and Metabolic Signature in Ulcerative Colitis Predicts Anti-Inflammatory Therapy Success
|
||
Not yet recruiting |
NCT05953402 -
A Study of Ozanimod in Pregnant Women With Ulcerative Colitis and Their Offspring
|
||
Recruiting |
NCT05316584 -
A Novel Remote Patient and Medication Monitoring Solution to Improve Adherence and PerSiStence With IBD Therapy
|
N/A | |
Recruiting |
NCT03950232 -
An Extension Study for Treatment of Moderately to Severely Active Ulcerative Colitis
|
Phase 3 | |
Completed |
NCT03124121 -
Study of the Golimumab Exposure-Response Relationship Using Serum Trough Levels
|
Phase 4 | |
Not yet recruiting |
NCT06100289 -
A Study of Vedolizumab in Children and Teenagers With Ulcerative Colitis or Crohn's Disease
|
Phase 3 | |
Withdrawn |
NCT04209556 -
A Study To Evaluate The Safety And Efficacy Of PF-06826647 In Participants With Moderate To Severe Ulcerative Colitis
|
Phase 2 | |
Terminated |
NCT00061282 -
Clotrimazole Enemas for Pouchitis in Children and Adults
|
Phase 1/Phase 2 | |
Recruiting |
NCT04398550 -
SCD vs. Mediterranean Diet Therapy in Ulcerative Colitis
|
N/A | |
Recruiting |
NCT04314375 -
Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of Budesonide Extended-release Tablets in Pediatric Subjects Aged 5 to 17 Years With Active, Mild to Moderate Ulcerative Colitis
|
Phase 4 | |
Active, not recruiting |
NCT04857112 -
Study Evaluating Efficacy and Safety of Amiselimod (MT-1303) in Mild to Moderate Ulcerative Colitis
|
Phase 2 | |
Completed |
NCT05051943 -
A Study of the Real-world Use of an Adalimumab Biosimilar and Evaluation of Nutritional Status on the Therapeutic Response
|
||
Active, not recruiting |
NCT04033445 -
A Study of Guselkumab in Participants With Moderately to Severely Active Ulcerative Colitis
|
Phase 2/Phase 3 | |
Recruiting |
NCT05428345 -
A Study of Vedolizumab SC Given to Adults With Moderate to Severe Ulcerative Colitis or Crohn's Disease in South Korea
|
||
Active, not recruiting |
NCT06221995 -
Energy Expenditure in Patients With Ulcerative Colitis Undergoing Surgery
|
||
Recruiting |
NCT04767984 -
Testing Atorvastatin to Lower Colon Cancer Risk in Longstanding Ulcerative Colitis
|
Phase 2 | |
Completed |
NCT02508012 -
Medico-economic Evaluation of the Therapeutic Drug Monitoring of Anti-TNF-α Agents in Inflammatory Bowel Diseases
|
N/A | |
Recruiting |
NCT06071312 -
FMT in Patients With Recurrent CDI and Ulcerative Colitis: Single Infusion Versus Sequential Approach
|
Phase 1/Phase 2 | |
Completed |
NCT03760003 -
Dose-Ranging Phase 2b Study of ABX464 in Moderate to Severe Ulcerative Colitis
|
Phase 2 | |
Not yet recruiting |
NCT05539625 -
Mini-MARVEL - Mitochondrial Antioxidant Therapy in Ulcerative Colitis
|
Phase 2 |